← Back
H
Hygieia
☰ Menu
×
Health
🧘
State
🦠
Microbiome
⌚
Wearables
🧬
Genetics
Reference
📇
Contacts
📋
Coverage
🔁
Reviews
🧠
Brain
🏁
Compare
Ops
🧭
Ops workspace
📥
Ingest review
☀
Brief
🧑⚕️
Coach
🩸
Tests
💬
Ask
💊
Protocols
Hygieia Brain
Current context
Current context
Keep this short and current. Hermes can read this before answering questions.
Current medications
Rosuvastatin 5 mg. Mounjaro started 2.5 mg on 2026-02-28 and is now at 7.5 mg. User previously reported taking rosuvastatin; Mounjaro start/current dose reconciled from reviewed supplement file and screenshot evidence.
Current supplements
Blueprint stack. Red yeast rice included in stack per user report.
Current findings
CAC 150. Minimal bilateral proximal internal carotid non-calcified plaque on carotid Doppler (30/07/2026). No significant stenosis. Latest loaded biomarker context: ApoB 0.6 g/L (2026-08-14); LDL 2.1 mmol/L (2026-08-14); Non-HDL 2.6 mmol/L (2026-08-14); hs-CRP 0.27 mg/L (2026-08-14); HbA1c 4.7 % (2026-08-14); Glucose 4.6 mmol/L (2026-08-14); Insulin 9 mU/L (2026-07-24).
Upcoming appointments / tests
CCTA booked for 2026-08-18.
Current priorities
Lower LDL / ApoB / Non-HDL further while watching side effects, especially glucose/insulin-resistance concerns. Clarify cleaner strategy: higher rosuvastatin vs ezetimibe vs simplifying red yeast rice overlap.
Doctor questions
Should I increase rosuvastatin or add ezetimibe? Does red yeast rice create unnecessary overlap with rosuvastatin? How should we monitor glucose / insulin resistance if lipid treatment is intensified? How should the CCTA result on 2026-08-18 change lipid target intensity?
Save current context
Open Hermes brief